SARS-CoV-2 is able to infect human cells by binding its spike (S ... activity by converting the latter to Ang (1-7). Virion binding to ACE2 for host cell entry leads to internalization of both via ...

Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other leading institutions, have ...

A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle ...

COVID-19 has continued to alarm public health, and although several therapeutics and vaccines have been developed, the development of effective vaccines or antibodies is challenging due to mutations ...

New research links multisystem inflammatory syndrome in children with COVID-19 to Epstein-Barr virus reactivation, revealing ...

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human ...

Background Infectious agents such as SARS-CoV-2 require strategies to contain outbreaks, particularly in hospitals where the ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

The landscape of drug discovery is evolving rapidly, driven by breakthroughs in AI, high-throughput screening and precision medicine. As researchers work to develop safer, more effective therapies, ...